New research indicates that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end traditional lifestyle plans.
Findings released in a prominent health publication points out that while overweight people can lose about a fifth of their total mass while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing such treatments need to be cognizant of the risk of quick rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of recovery implies a reversion to original mass within about 18 months.
Analyzing Treatments
The research, which looked at 37 of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
The team emphasize that individuals who shed pounds through diet and exercise typically see a slower weight regain—around 100 grams monthly—once they finish.
Understanding the Quick Rebound
Experts propose the way of the jabs accounts for the heightened weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of the hormone levels far above than normal might result in the body to produce less of its own natural GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement leads to hunger is no longer kept in check, making overeating much more probable."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians argue that, considering the high risk of weight regain, the treatment might need to be life-long.
This view is reinforced by pharmaceutical companies, who note that the findings "highlight the chronic character of excess weight," similar to managing conditions like hypertension.
Patient Accounts
Individuals who have discontinued the jabs describe a intense return of hunger.
"It was like a switch activating and I was suddenly starving," said an individual.
This challenge is worsened if individuals have not developed lasting lifestyle or habit modifications during therapy.
Growing Use
Survey data suggest that millions of adults in the UK have tried these injections in the past year, with interest remaining high.
- Adoption is greater among women compared to men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Finally, clinicians caution that while the jabs are effective tools for weight loss, they are not a permanent fix and long-term success likely depends on ongoing lifestyle changes.
